Email this article Difficulties in diagnosing ALK-negative anaplastic large cell lymphoma manifesting from a skin lesion
- Authors: Bulanova N.V.1, Semochkin S.V.2,3
-
Affiliations:
- Volgograd Regional Clinical Oncology Center
- P. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Center
- The Russian National Research Medical University named after N.I. Pirogov
- Issue: Vol 25, No 6 (2022)
- Pages: 25-32
- Section: DERMATO-ONCOLOGY
- URL: https://journals.rcsi.science/1560-9588/article/view/132584
- DOI: https://doi.org/10.17816/dv115012
- ID: 132584
Cite item
Open Access
Access granted
Subscription Access
Abstract
Anaplastic large cell lymphoma is a rare form of non-Hodgkin's lymphoma that requires an early diagnosis and urgent therapy due to aggressive tumor process. Clinically, most non-Hodgkin's lymphoma present with lymphoadenopathy and В-symptoms (such as weakness, drowsiness, fatigue, subfebrile fever, profuse night sweats). However, anaplastic large cell lymphoma may present with nonspecific skin lesions with minimal or no B-symptoms. The skin lesions are heterogeneous, which may also delay verification of the diagnosis.
We present a case of widespread anaplastic large cell lymphoma skin lesions mimicking a case of erysipelas, which progressed rapidly from a single rash on the wrist to an extensive lesion of the right breast within 1 month. Prior to verification of the diagnosis, the patient was treated for erysipelas, pyoderma, and herpes zoster with no response to therapy. Immunohistochemical examination of a skin biopsy confirmed the diagnosis of ALK-negative anaplastic large cell lymphoma. At the time of publication, the patient had completed 1 course of the CHOEP regimen, and 6 cycles of the program were planned.
Our case demonstrates the necessity of a broad differential diagnosis of rashes torpid to the current therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Natalia V. Bulanova
Volgograd Regional Clinical Oncology Center
Author for correspondence.
Email: kmn.nv.bulanova@yandex.ru
ORCID iD: 0000-0002-8724-0714
SPIN-code: 5143-7381
ResearcherId: rid33435
MD, Cand. Sci. (Med.)
Russian Federation, VolgogradSergey V. Semochkin
P. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Center; The Russian National Research Medical University named after N.I. Pirogov
Email: semochkin_sv@rsmu.ru
ORCID iD: 0000-0002-8129-8114
SPIN-code: 8926-3289
MD, Dr. Sci. (Med.), Professor
Russian Federation, Moscow; MoscowReferences
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
- Zain JM, Hanona P. Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management. Am J Hematol. 2021;96(8):1027–1046. doi: 10.1002/ajh.26270
- Moodley N, Nombona P, Mosam A. Primary cutaneous anaplastic large-cell lymphoma. Dermatopathology. 2019;6(2):163–169. doi: 10.1159/000500259
- Vose J, Armitage J, Weisenburger D. International peripherial T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. doi: 10.1200/JCO.2008.16.4558
- Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013;85(2):206–215. doi: 10.1016/j.critrevonc.2012.06.004
- Shustov A, Cabrera ME, Civallero M, et al. ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project. Blood Adv. 2021;5, N 3. P. 640–648. doi: 10.1182/bloodadvances.2020001581
- Philippe E, Creech KT, Cook N, Segura J. Recurrent primary cutaneous anaplastic large cell lymphoma with systemic involvement: A case report and literature review. Cureus. 2021;13(4):e14284. doi: 10.7759/cureus.14284
- Magro CM, Momtahen S, Kiuru M. Primary cutaneous small cell variant of anaplastic large cell lymphoma: A case series and review of the literature. Am J Dermatopathol. 2017;39(12):877–889. doi: 10.1097/DAD.0000000000000908
- Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol. 2017;34(1):22–35. doi: 10.1053/j.semdp.2016.11.005
- Chkhikvadze VD, Kolesnik AIu, Meskikh EV, Lagozhina IA. Edematous-infiltrative breast cancer: expediency of its division into primary and secondary forms. P.A. Herzen journal of Oncology. 2015;4(1):21–24. (In Russ).
Supplementary files
